Deborah J. Wexler MD, MScAssociate Professor of Medicine, Harvard Medical School; Chief, Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts
Dr. Deborah J. Wexler's research focuses on clinical effectiveness in type 2 diabetes. In addition, she is on the Editorial Board of Diabetes Care, and is a reviewer for multiple journals.
Dr. Wexler reports serving on Data Monitoring Committees for trials of oral semaglutide sponsored by Novo Nordisk.
Recent Contributions to PracticeUpdate:
- Hemoglobin A1c Reduction and CV Risk Improvement: Correlation, Causation and Clinical Recommendations
- Rationale and Clinical Utility of Sulfonylureas in Contemporary Practice
- Comparative Effectiveness of a DPP-4 Inhibitor, a Sulfonylurea, a GLP-1 Agonist, and Basal Insulin: Data From the GRADE Trial
- ADA 2021: Recommendations From Dr. Deborah Wexler
- 2020 Top Stories in Diabetes: The DAPA-CKD Trial
- Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
- 2019 Top Stories in Diabetes: The CREDENCE Trial
- Cannabis Use Is Associated With Increased Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes
- Even Moderate Weight Loss After Diabetes Diagnosis Improves Long-Term Cardiovascular Risk
- Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease